These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 29729414

  • 1. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.
    Reynaldo-Fernández G, Solozábal J, Amaro D, Fernández-Sánchez EM, Rodríguez-Vera L, Bermejo M, Mangas-Sanjuan V, Troconiz IF.
    Eur J Pharm Sci; 2018 Jul 30; 120():123-132. PubMed ID: 29729414
    [Abstract] [Full Text] [Related]

  • 2. Safety and biosimilarity of ior(®) EPOCIM compared with Eprex(®) based on toxicologic, pharmacodynamic, and pharmacokinetic studies in the Sprague-Dawley rat.
    Pucaj K, Riddle K, Taylor SR, Ledon N, Bolger GT.
    J Pharm Sci; 2014 Nov 30; 103(11):3432-3441. PubMed ID: 25250536
    [Abstract] [Full Text] [Related]

  • 3. A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM.
    Reynaldo G, Rodríguez L, Menéndez R, Solazábal J, Amaro D, de Los A Becquer M, Colom Y, Gil H, Polo JC, Castañeda G, Jiménez-Vélez B, Duconge J, Fernández-Sánchez EM.
    J Pharm Pharmacogn Res; 2018 Nov 30; 6(3):179-190. PubMed ID: 30739984
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
    Olsson-Gisleskog P, Jacqmin P, Perez-Ruixo JJ.
    Clin Pharmacokinet; 2007 Nov 30; 46(2):159-73. PubMed ID: 17253886
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.
    Veng-Pedersen P, Freise KJ, Schmidt RL, Widness JA.
    J Pharm Pharmacol; 2008 Oct 30; 60(10):1321-34. PubMed ID: 18812025
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetic analysis of pegylated human erythropoietin in rats.
    Jolling K, Ruixo JJ, Hemeryck A, Piotrovskij V, Greway T.
    J Pharm Sci; 2004 Dec 30; 93(12):3027-38. PubMed ID: 15503315
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hyperhydration Effect on Pharmacokinetic Parameters and Detection Sensitivity of Recombinant Human Erythropoietin in Urine and Serum Doping Control Analysis of Males.
    Athanasiadou I, Dokoumetzidis A, Voss SC, El Saftawy W, Al-Maadheed M, Valsami G, Georgakopoulos C.
    J Pharm Sci; 2019 Jun 30; 108(6):2162-2172. PubMed ID: 30684541
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of bioactivity and pharmacokinetic characteristics of PEGylated P.pastoris-expressed erythropoietin.
    Maleki A, Najafabadi AR, Roohvand F, Shafiee A, Khanahmad H, Faghihi H, Hedayati MH, Tajerzadeh H.
    Drug Deliv; 2011 Nov 30; 18(8):570-7. PubMed ID: 21892875
    [Abstract] [Full Text] [Related]

  • 13. Erythropoietin-coated ZP-microneedle transdermal system: preclinical formulation, stability, and delivery.
    Peters EE, Ameri M, Wang X, Maa YF, Daddona PE.
    Pharm Res; 2012 Jun 30; 29(6):1618-26. PubMed ID: 22258935
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
    Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ.
    J Clin Pharmacol; 2004 Sep 30; 44(9):991-1002. PubMed ID: 15317827
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, Lagarde-Ampudia M, Casanova-Kutsareva Y, Avila-Albuerne Y, Vargas-Batista A, Bobillo-López H, Herrera-Valdés R, López-Saura PA, Bioequivalence Study of Erythropoietin Group.
    BMC Nephrol; 2005 May 23; 6():5. PubMed ID: 15910687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.